Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

A total of 4 out of 10 women who had a professional activity stopped working after discovering breast cancer, according to research conducted by Datafilha at the request of the pharmaceutical company Astrazeneca.
Read more (10/16/2024)

AstraZeneca

Breast Cancer

São Paulo

Folha de S.Paulo

Women suffer from job loss after breast cancer diagnosis, Datafilha points out

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing r

Los Angeles, California

Los Angeles

EuropaWire.eu

AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation

Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.

PharmaVOICE

Want to launch a blockbuster? An AstraZeneca exec breaks it down.

WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. The trial demonstrated that when AIRSUPRA is used as a rescue medication, it significantly lowers the chance of severe asthma attacks compared to the traditional use of albuterol alone. Conducted on patients with intermittent or mild per…

Wilmington, Delaware

Wilmington

MyChesCo

AstraZeneca's AIRSUPRA Proven Effective in Reducing Severe Asthma Attacks

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses examples of how effective communication can resolve supply chain issues.

Pharmaceutical Commerce

Effective Resolutions to Supply Chain Issues

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

China

pharmaceutical-technology.com

ENHERTU gains conditional approval in China

(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China for the treatment of patients with u

Maryland

Enhertu by AstraZeneca and Daiichi Sankyo Approved in China as First HER2-Directed Therapy for Metastatic Lung Cancer

AstraZeneca (LSE: AZN), Unilever (LSE: ULVR), and GSK (LSE: GSK) are some of the largest businesses in the FTSE 100. All are blue-chip companies that are popular with investors. Wondering what kind of dividends they’re likely to serve up in the year ahead? Here’s a look at the dividend forecasts for 2025. Ignore the low yield Let’s start with pharmaceutical company AstraZeneca. Because it’s the largest business in the Footsie with a market cap o…

The Motley Fool UK

Here are the 2025 dividend forecasts for FTSE giants Unilever, GSK, and AstraZeneca

Endpoints News

Pharmacy Times

Clinical Trials Arena

Benzinga

Pharmaphorum

The Asthma Society of Ireland has warned that over-use of steroid medication may cause more harm than good.

Research

Dublin, Ireland

Dublin

RTÉ

Irish Medical Times

Dataemia

Asthma Society warns of over-use of steroid medication

The Ministry of Health has recognized the 'causal link' between the administration of the drug and human death

Vaccines

Italy

ilgiornale.it

35-year-old dead after Astrazeneca vaccine: green light for compensation

MSD reveals the data that could unlock filings for clesrovimab, a rival to Sanofi and AstraZeneca's Beyfortus for preventing infant RSV infections

News from AstraZeneca